GZA Sint-Vincentius
- Address
- lock Available on a paid plan
Irritable Bowel Syndrome Research
The gastroenterology department at GZA Sint-Vincentius is conducting a study that compares two oral agents to improve symptoms and daily functioning in patients with Irritable Bowel Syndrome.
- Comparative efficacy of ebastine versus mebeverine
- Impact on health‑related quality of life
- Measurement of quality‑adjusted life years
- Patient‑reported outcome assessments
Results aim to guide clinicians toward the most effective symptom‑relief strategy for this functional bowel disorder.
Ulcerative Colitis Trials
Researchers at the site are evaluating a novel oral compound for patients with moderately to severely active ulcerative colitis, focusing on both endoscopic healing and clinical remission.
- Efficacy of ABX464 compared with placebo
- Endoscopic improvement as primary endpoint
- Sustained clinical remission during maintenance phase
- Safety and tolerability profile of the investigational drug
The study seeks to expand therapeutic options for a disease that significantly affects quality of life.
Crohn's Disease Surgical Study
A multicentric investigation at GZA Sint-Vincentius examines the optimal timing of biological therapy after ileocolonic resection in patients with Crohn's disease who are at risk for postoperative recurrence.
- Systematic early initiation versus endoscopy‑driven initiation of therapy
- Postoperative endoscopic recurrence rates
- Role of risk factors in guiding treatment decisions
- Long‑term disease control and patient outcomes
Findings will inform strategies to prevent disease recurrence and improve surgical prognosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in GZA Sint-Vincentius
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis | Abivax | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obefazimod | 2 | Unknown | 2023-06-08 | 2023-06-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.